肺癌基因组检测药物市场－全球产业规模、份额、趋势、机会和预测，按技术、样本类型、检测组类型、最终用户、地区和竞争格局划分，2020-2030年预测

全球肺癌基因组检测市场规模预计将从2024年的19亿美元成长至2030年的25.9亿美元，复合年增长率（CAGR）为5.30%。肺癌基因组检测涵盖肿瘤脱氧核糖核酸（DNA）的分析，旨在识别特定的基因突变或改变，从而为患者选择个人化的治疗策略。市场成长的主要驱动因素包括全球肺癌发生率的上升、基因组定序技术（例如新一代定序）的不断进步，以及肿瘤学领域对精准医疗方法日益增长的需求。

主要市场驱动因素

全球肺癌基因组检测药物市场受到全球肺癌发生率不断上升的显着影响。日益加重的疾病负担使得人们迫切需要先进的诊断工具，以进行精准的患者分层并指导标靶治疗介入。

主要市场挑战

先进基因组检测的高昂成本严重阻碍了全球肺癌基因组检测药物市场的成长。高昂的检测费用直接限制了病患的就医途径，尤其是在医疗系统面临预算限製或尚未建立完善的报销机制的情况下。

主要市场趋势

人工智慧和机器学习显着提升了肺癌基因组解读能力，并提高了复杂资料分析的速度和准确性。这些技术能够精准识别对标靶治疗至关重要的可操作突变。

目录

第一章：产品概述

第二章：研究方法

第三章：执行概要

第四章：顾客之声

第五章：全球肺癌基因组检测药物市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依技术分类（聚合酶炼式反应、次世代定序、萤光原位杂交、其他）
  • 依样本类型（组织切片、液体切片）
  • 依检测组类型（多基因检测组、单基因检测组）
  • 按最终使用者（研究机构、医院和诊所、诊断实验室、其他）
  • 按地区
  • 按公司（2024 年）
• 市场地图

第六章：北美肺癌基因组检测药物市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲肺癌基因组检测药物市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区肺癌基因组检测药物市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲肺癌基因组检测药物市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 南非

第十章：南美洲肺癌基因组检测药物市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章：市场动态

• 司机
• 挑战

第十二章：市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章：全球肺癌基因组检测药物市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商议价能力
• 顾客的力量
• 替代产品的威胁

第十五章：竞争格局

• QIAGEN NV
• Agilent Technologies Inc.
• Thermo Fisher Scientific Inc.
• Quest Diagnostics Incorporated
• Laboratory Corporation of America Holdings
• CENTOGENE NV
• BGI Genomics Co. Ltd.
• CeGaT GmbH
• Illumina Inc.
• F. Hoffmann-La Roche Ltd

第十六章：策略建议

第17章调查会社について・免责事项

The Global Lung Cancer Genomic Testing Medicine Market will grow from USD 1.90 Billion in 2024 to USD 2.59 Billion by 2030 at a 5.30% CAGR. Lung cancer genomic testing medicine encompasses the analysis of tumor deoxyribonucleic acid to identify specific genetic mutations or alterations, enabling the selection of personalized therapeutic strategies for patients. The market's growth is primarily driven by the rising global incidence of lung cancer, continuous advancements in genomic sequencing technologies such as Next-Generation Sequencing, and an increasing imperative for precision medicine approaches in oncology.

Key Market Drivers

The market for global lung cancer genomic testing medicine is significantly influenced by the increasing worldwide incidence of lung cancer. This escalating disease burden creates an urgent demand for advanced diagnostic tools to facilitate precise patient stratification and guide targeted therapeutic interventions. Lung cancer consistently ranks as a leading cause of cancer-related mortality globally, necessitating innovation in diagnostic capabilities.

Key Market Challenges

The substantial cost associated with advanced genomic testing represents a significant impediment to the growth of the Global Lung Cancer Genomic Testing Medicine Market. High test expenses directly limit patient access, particularly in healthcare systems facing budgetary constraints or where comprehensive reimbursement policies are not fully established. This financial barrier can deter clinicians from ordering these essential tests and prevent patients from undergoing molecular profiling, thereby restricting the overall adoption rate of precision medicine strategies in lung cancer.

Key Market Trends

Artificial intelligence and machine learning are significantly enhancing lung cancer genomic interpretation, improving speed and accuracy for complex data analysis. These technologies enable precise identification of actionable mutations crucial for targeted therapies. For instance, the International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on Lung Cancer showcased an AI tool, DeepGEM, for gene mutation prediction from histopathology slides, with data from 3,658 patients analyzed.

Key Market Players

• QIAGEN NV
• Agilent Technologies Inc.
• Thermo Fisher Scientific Inc.
• Quest Diagnostics Incorporated
• Laboratory Corporation of America Holdings
• CENTOGENE N.V.
• BGI Genomics Co. Ltd.
• CeGaT GmbH
• Illumina Inc.
• F. Hoffmann-La Roche Ltd

Report Scope:

In this report, the Global Lung Cancer Genomic Testing Medicine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Lung Cancer Genomic Testing Medicine Market, By Technology:

• Polymerase Chain Reaction
• Next-Generation Sequencing
• Fluorescence In-Situ Hybridization
• Others

Lung Cancer Genomic Testing Medicine Market, By Sample Type:

• Tissue Biopsy
• Liquid Biopsy

Lung Cancer Genomic Testing Medicine Market, By Panel Type:

• Multi-Gene Panel
• Single-Gene Panel

Lung Cancer Genomic Testing Medicine Market, By End-User:

• Research Organization
• Hospitals & Clinics
• Diagnostic Laboratories
• Others

Lung Cancer Genomic Testing Medicine Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Lung Cancer Genomic Testing Medicine Market.

Available Customizations:

Global Lung Cancer Genomic Testing Medicine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Lung Cancer Genomic Testing Medicine Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Technology (Polymerase Chain Reaction, Next-Generation Sequencing, Fluorescence In-Situ Hybridization, Others)
  • 5.2.2. By Sample Type (Tissue Biopsy, Liquid Biopsy)
  • 5.2.3. By Panel Type (Multi-Gene Panel, Single-Gene Panel)
  • 5.2.4. By End-User (Research Organization, Hospitals & Clinics, Diagnostic Laboratories, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America Lung Cancer Genomic Testing Medicine Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Technology
  • 6.2.2. By Sample Type
  • 6.2.3. By Panel Type
  • 6.2.4. By End-User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Lung Cancer Genomic Testing Medicine Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Technology
      • 6.3.1.2.2. By Sample Type
      • 6.3.1.2.3. By Panel Type
      • 6.3.1.2.4. By End-User
  • 6.3.2. Canada Lung Cancer Genomic Testing Medicine Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Technology
      • 6.3.2.2.2. By Sample Type
      • 6.3.2.2.3. By Panel Type
      • 6.3.2.2.4. By End-User
  • 6.3.3. Mexico Lung Cancer Genomic Testing Medicine Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Technology
      • 6.3.3.2.2. By Sample Type
      • 6.3.3.2.3. By Panel Type
      • 6.3.3.2.4. By End-User

7. Europe Lung Cancer Genomic Testing Medicine Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Technology
  • 7.2.2. By Sample Type
  • 7.2.3. By Panel Type
  • 7.2.4. By End-User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Lung Cancer Genomic Testing Medicine Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Technology
      • 7.3.1.2.2. By Sample Type
      • 7.3.1.2.3. By Panel Type
      • 7.3.1.2.4. By End-User
  • 7.3.2. France Lung Cancer Genomic Testing Medicine Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Technology
      • 7.3.2.2.2. By Sample Type
      • 7.3.2.2.3. By Panel Type
      • 7.3.2.2.4. By End-User
  • 7.3.3. United Kingdom Lung Cancer Genomic Testing Medicine Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Technology
      • 7.3.3.2.2. By Sample Type
      • 7.3.3.2.3. By Panel Type
      • 7.3.3.2.4. By End-User
  • 7.3.4. Italy Lung Cancer Genomic Testing Medicine Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Technology
      • 7.3.4.2.2. By Sample Type
      • 7.3.4.2.3. By Panel Type
      • 7.3.4.2.4. By End-User
  • 7.3.5. Spain Lung Cancer Genomic Testing Medicine Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Technology
      • 7.3.5.2.2. By Sample Type
      • 7.3.5.2.3. By Panel Type
      • 7.3.5.2.4. By End-User

8. Asia Pacific Lung Cancer Genomic Testing Medicine Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Technology
  • 8.2.2. By Sample Type
  • 8.2.3. By Panel Type
  • 8.2.4. By End-User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Lung Cancer Genomic Testing Medicine Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Technology
      • 8.3.1.2.2. By Sample Type
      • 8.3.1.2.3. By Panel Type
      • 8.3.1.2.4. By End-User
  • 8.3.2. India Lung Cancer Genomic Testing Medicine Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Technology
      • 8.3.2.2.2. By Sample Type
      • 8.3.2.2.3. By Panel Type
      • 8.3.2.2.4. By End-User
  • 8.3.3. Japan Lung Cancer Genomic Testing Medicine Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Technology
      • 8.3.3.2.2. By Sample Type
      • 8.3.3.2.3. By Panel Type
      • 8.3.3.2.4. By End-User
  • 8.3.4. South Korea Lung Cancer Genomic Testing Medicine Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Technology
      • 8.3.4.2.2. By Sample Type
      • 8.3.4.2.3. By Panel Type
      • 8.3.4.2.4. By End-User
  • 8.3.5. Australia Lung Cancer Genomic Testing Medicine Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Technology
      • 8.3.5.2.2. By Sample Type
      • 8.3.5.2.3. By Panel Type
      • 8.3.5.2.4. By End-User

9. Middle East & Africa Lung Cancer Genomic Testing Medicine Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Technology
  • 9.2.2. By Sample Type
  • 9.2.3. By Panel Type
  • 9.2.4. By End-User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Lung Cancer Genomic Testing Medicine Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Technology
      • 9.3.1.2.2. By Sample Type
      • 9.3.1.2.3. By Panel Type
      • 9.3.1.2.4. By End-User
  • 9.3.2. UAE Lung Cancer Genomic Testing Medicine Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Technology
      • 9.3.2.2.2. By Sample Type
      • 9.3.2.2.3. By Panel Type
      • 9.3.2.2.4. By End-User
  • 9.3.3. South Africa Lung Cancer Genomic Testing Medicine Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Technology
      • 9.3.3.2.2. By Sample Type
      • 9.3.3.2.3. By Panel Type
      • 9.3.3.2.4. By End-User

10. South America Lung Cancer Genomic Testing Medicine Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Technology
  • 10.2.2. By Sample Type
  • 10.2.3. By Panel Type
  • 10.2.4. By End-User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Lung Cancer Genomic Testing Medicine Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Technology
      • 10.3.1.2.2. By Sample Type
      • 10.3.1.2.3. By Panel Type
      • 10.3.1.2.4. By End-User
  • 10.3.2. Colombia Lung Cancer Genomic Testing Medicine Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Technology
      • 10.3.2.2.2. By Sample Type
      • 10.3.2.2.3. By Panel Type
      • 10.3.2.2.4. By End-User
  • 10.3.3. Argentina Lung Cancer Genomic Testing Medicine Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Technology
      • 10.3.3.2.2. By Sample Type
      • 10.3.3.2.3. By Panel Type
      • 10.3.3.2.4. By End-User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Lung Cancer Genomic Testing Medicine Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. QIAGEN NV
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Agilent Technologies Inc.
• 15.3. Thermo Fisher Scientific Inc.
• 15.4. Quest Diagnostics Incorporated
• 15.5. Laboratory Corporation of America Holdings
• 15.6. CENTOGENE N.V.
• 15.7. BGI Genomics Co. Ltd.
• 15.8. CeGaT GmbH
• 15.9. Illumina Inc.
• 15.10. F. Hoffmann-La Roche Ltd

16. Strategic Recommendations

17. About Us & Disclaimer